Stock Report

All about this stock under one free report Last Updated: 17-May-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Onconova Therapeutics Inc. (ONTX)

Stock Card factsheet share-fund-plan-icon

$0.64

up-down-arrow $-7.29 (-91.91%)

As on 02-May-2024 09:30EDT

Market cap

info icon

$21 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

1.9

Div. Yield

info icon

0 %

Onconova Therapeutics (ONTX) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.63 High: 0.67

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $-4 Mln

  • ROEROE information

    -0.8 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    28.71

  • EV/EBITDAEV/EBITDA information

    0

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $--

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    21,003,400

10 Years Aggregate

CFO

$-248.83 Mln

EBITDA

$-270.69 Mln

Net Profit

$-251.73 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Onconova Therapeutics (ONTX)
-14.5 -35.8 -10.5 -43.2 -61.0 -60.0 -62.9
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 02-May-2024  |  *As on 15-May-2026  |  #As on 26-Oct-2023
Company
2023
2022
2021
2020
2019
2018
2017
Onconova Therapeutics (ONTX)
16.2 -74.5 -63.5 21.6 -81.8 -90.5 -33.9
S&P Small-Cap 600
13.9 -17.4 25.3 9.6 20.9 -9.7 11.7
BSE Sensex
18.7 4.4 22.0 15.8 14.4 5.9 27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Onconova Therapeutics (ONTX)

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase...  inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.  Read more

  • CEO, President & Director

    Dr. Steven M. Fruchtman M.D.

  • CEO, President & Director

    Dr. Steven M. Fruchtman M.D.

  • Headquarters

    Newtown, PA

  • Website

    https://www.onconova.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Onconova Therapeutics (ONTX)

The share price of Onconova Therapeutics Inc (ONTX) is $0.64 (NASDAQ) as of 02-May-2024 09:30 EDT. Onconova Therapeutics Inc (ONTX) has given a return of -60.97% in the last 3 years.

Since, TTM earnings of Onconova Therapeutics Inc (ONTX) is negative, P/E ratio is not available.
The P/B ratio of Onconova Therapeutics Inc (ONTX) is 1.86 times as on 02-May-2024, a 69 discount to its peers’ median range of 6.00 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2023
--
--
2022
--
--
2021
--
--
2020
--
--
2019
--
--

The 52-week high and low of Onconova Therapeutics Inc (ONTX) are Rs -- and Rs -- as of 17-May-2026.

Onconova Therapeutics Inc (ONTX) has a market capitalisation of $ 21 Mln as on 02-May-2024. As per SEBI classification, it is a Small Cap company.

Before investing in Onconova Therapeutics Inc (ONTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.